% | $
Quotes you view appear here for quick access.

Incyte Corporation Message Board

  • tjnelis tjnelis Oct 22, 2013 6:35 AM Flag

    just for you maddi, from nvs report

    Jakavi (USD 48 million) grew as an oral inhibitor of the JAK 1 and JAK 2 tyrosine kinases. It is the first JAK inhibitor indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis. Jakavi (ruxolitinib) is currently approved in more than 50 countries, including EU member states, Canada, Australia, Mexico and Argentina, with additional regulatory filings underway. Novartis licensed ruxolitinib from Incyte Corporation for development and commercialization outside the US.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
79.98+1.25(+1.58%)Jun 30 4:00 PMEDT